Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MDUFA IV (And More) Is Law: Trump Signs A Health-Care Bill

Executive Summary

President Trump's eleventh-hour signature on the FDA Reauthorization Act puts into play about $1bn in device user-fee collections from industry through FY 2022, new US FDA performance goals and a range of device process enhancements and reforms supported by industry.


Related Content

FDA Clarifies Export-Denial Appeals Process
Senate Approves FDA User Fee Reauthorization Bill On 94-1 Vote
Senate To Consider User Fee Bill Soon, As Hopes For BCRA Passage With Device Tax Repeal Fade
With Gottlieb Sworn In, His Focus Should Be On Quick User-Fee Passage, Industry Advocates Say
Legislation Would Streamline Risk-Classification For Device Accessories
Stakeholders Support OTC Hearing Aids At FTC Summit
House Bill Clarifies CDRH Lead For New Imaging Indications For Devices Using Contrast
Trump Budget: FDA-Regulated Firms Should Pay 'Their Share' In User Fees
New Bill Aims To Bring Consistency, Transparency To US FDA Inspections
Pilot Of New US Evaluation System Will Include At Least Two Devices





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts